Значение эпидермального барьера и сенсибилизации к бытовым аллергенам на развитие атопического марша в обосновании первичной профилактики
https://doi.org/10.20538/1682-0363-2018-2-114-120
Аннотация
Об авторах
Е. Е. ВарламовРоссия
канд. мед. наук, ст. науч. сотрудник, зав. отделением аллергологии и клинической иммунологии,
125412, г. Москва, ул. Талдомская, 2
А. Н. Пампура
Россия
д-р мед. наук, зав. отделением отделения аллергологии и клинической иммунологии,
125412, г. Москва, ул. Талдомская, 2
А. И. Асманов
Россия
канд. мед. наук, руководитель научного отдела острой и хронической патологии уха, горла и носа,
125412, г. Москва, ул. Талдомская, 2
Список литературы
1. Dharmage S.C., Lowe A.J., Matheson M.C. et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014; 69 (1): 17–27. DOI: 10.1111/all.12268.
2. Hill D.A., Spergel J.M. The atopic march. Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018; 120: 131–137. DOI: 10.1016/j.anai.2017.10.037.
3. Pearce N., Aït-Khaled N., Beasley R. et al. ISAAC Phase Three Study Group. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007; 62: 758–766. DOI: 10.1136/thx.2006.070169.
4. Bantz S.K., Zhu Z., Zheng T. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J. Clin. Cell. Immunol. 2014; 5 (2): 202. DOI: 10.4172/2155-9899.1000202.
5. Strachan D.P., Butland B.K., Anderson H.R. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ. 1996; 312: 1195–1199. DOI: 10.1136/bmj.312.7040.1195.
6. Tran M.M., Lefebvre D.L., Dharma C. et al. Canadian Healthy Infant Longitudinal Development Study investigators. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J. Allergy Clin. Immunol. 2018; 141 (2): 601–607. DOI: 10.1016/j.jaci.2017.08.024.
7. Somanunt S., Chinratanapisit S., Pacharn P. et al. The natural history of atopic dermatitis and its association with Atopic March. Asian Pac. J. Allergy Immunol. 2017; 35 (3): 137–143. DOI: 10.12932/AP0825.
8. Belgrave D.C., Granell R., Simpson A. et al. Developmental profiles of eczema, wheeze, and rhinitis: two populationbased birth cohort studies. PLoS Med. 2014; 11: e1001748. DOI.org/10.1371/journal.pmed.1001748.
9. Nemoto-Hasebe I., Akiyama M., Nomura T. et al. Clinical severity correlates with impaired barrier in filaggrinrelated eczema. Journal of Investigative Dermatology. 2009; 129 (3): 682–689. DOI: 10.1038/jid.2008.280.
10. Elias P., Feingold K. Skin Barrier. New York; London, Informa Healthcare, 2005: 632.
11. Krien P., Kermici M. Evidence for the existence of a self-regulated enzymatic process within human stratum corneum-an unexpected role for urocanic acid. J. Invest Dermatol. 2000; 115 (3): 414–420. DOI: 10.1046/j.1523- 1747.2000.00083.x.
12. Варламов Е.Е., Тагирова М.К., Комова Е.Г. и др. Клиническое значение мутаций гена FLG у детей с атопическим дерматитом. Российский вестник перинатологии и педиатрии. 2015; 2: 87–91. [Varlamov E.E., Tagirova M.K., Komova E.G. et al. Clinical significance of FLG gene mutations in children with atopic dermatitis. Rossiyskiy vestnik perinatologii i pediatrii – The Russian Bulletin of Perinatology and Pediatrics. 2015; 2: 87–91 (in Russ.)].
13. Ziyab A.H., Karmaus W., Zhang H. et al. Association of filaggrin variants with asthma and rhinitis: is eczema or allergic sensitization status an effect modifier? Int. Arch. Allergy Immunol. 2014; 164 (4): 308–318. DOI: 10.1159/000365990.
14. Dębińska A., Danielewicz H., Drabik-Chamerska A. et al. Filaggrin loss-of-function mutations as a predictor for atopic eczema, allergic sensitization and eczema-associated asthma in Polish children population. Adv. Clin. Exp. Med. 2017; 26 (6): 991–998. DOI: 10.17219/acem/61430.
15. Sala-Cunill A., Bartra J., Dalmau G. et al. Prevalence of asthma and severity of allergic rhinitis comparing 2 perennial allergens: house dust mites and parietaria judaica pollen. J. Investig. Allergol. Clin. Immunol. 2013; 23: 145–151.
16. Calderon M.A., Kleine-Tebbe J., Linneberg A. et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J. Allergy Clin. Immunol. 2015; 3: 843–855. DOI: 10.1016/j.jaip.2015.06.019.
17. Sánchez-Borges M., Fernandez-Caldas E., Thomas W.R. et al. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ. J. 2017; 10 (1): 14. DOI: 10.1186/ s40413-017-0145-4.
18. Chapman M.D., Platts-Mills T.A. Purification and characterization of the major allergen from Dermatophagoides pteronyssinus-antigen P1. J. Immunol. 1980; 125: 587–592.
19. Roche N., Chinet T.C., Belouchi N. et al. Dermatophagoides pteronyssinus and bioelectric properties of airway epithelium: role of cysteine proteases. Eur. Respir. J. 2000; 16: 309–315.
20. Pichavant M., Charbonnier A., Taront S. et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J. Allergy Clin. Immunol. 2005; 115: 771–778. DOI: 10.1016/j.jaci.2004.11.043.
21. Adam E., Hansen K.K., Astudillo O.F. et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J. Biol. Chem. 2006; 281: 6910–6923. DOI: 10.1074/jbc.M507140200.
22. Halim T.Y.F., Steer C.A., Matha L. et al. Group 2 innate lymphoid cells are critical for the Initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014; 40: 425–435. DOI: 10.1016/j.immuni.2014.01.011.
23. Ghaemmaghami A.M., Gough L., Sewell H.F. et al. Proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level. Clin. Exp. Allergy. 2002; 32: 1468–1475. DOI: 10.1046/j.1365-2745.2002.01504.x.
24. Schulz O., Sewell H.F., Shakib F. The interaction between the dust mite antigen Der p 1 and cell-signalling molecules in amplifying allergic disease. Clin. Exp. Allergy. 1999; 29: 439–444. DOI: 10.1046/j.1365-2222.1999.00464.x.
25. Wan H., Winton H.L., Soeller C. et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin. Exp. Allergy. 2001; 31; 279–294. DOI: 10.1046/j.1365-2222.2001.00970.x.
26. Brown S.J., Relton C.L., Liao H. et al. Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. J. Allergy Clin. Immunol. 2008: 121: 940–946. DOI: 10.1016/j.jaci.2008.01.013.
27. Flohr C., Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014; 69: 3–16. DOI: 10.1111/all.12270.
28. Harris J.M., Williams H.C., White C. et al. Early allergen exposure and atopic eczema. Br. J. Dermatol. 2007; 156: 698–704. DOI: 10.1111/j.1365-2133.2006.07710.x.
29. Arroyave W.D., Rabito F.A., Carlson J.C. et al. Impermeable dust mite covers in the primary and tertiary prevention of allergic disease: a meta-analysis. Arch. Dermatol. 2007; 143: 12: 1570–1577. DOI: 10.1016/j. anai.2014.01.006.
30. Wilson J.M., Platts-Mills T.A.E. Home environmental interventions for house dust mite. J Allergy Clin. Immunol. Pract. 2018; 6(1): 1–7. DOI: 10.1016/j.jaip.2017.10.003.
31. Lowe A.J., Leung D.Y.M., Tang M.L.K. et al. The skin as a target for prevention of the atopic march. Ann. Allergy Asthma Immunol. 2018; 120 (2): 145–151. DOI: 10.1016/j.anai.2017.11.023.
32. Horimukai K., Morita K., Narita M. et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J. Allergy Clin. Immunol. 2014; 134 (4): 824–830. DOI: 10.1016/j.jaci.2014.07.060.
33. Simpson E.L., Chalmers J.R., Hanifin J.M. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J. Allergy Clin. Immunol. 2014; 134: 818–823. DOI: 10.1016/j.jaci.2014.08.005.
Рецензия
Для цитирования:
Варламов Е.Е., Пампура А.Н., Асманов А.И. Значение эпидермального барьера и сенсибилизации к бытовым аллергенам на развитие атопического марша в обосновании первичной профилактики. Бюллетень сибирской медицины. 2018;17(2):114-120. https://doi.org/10.20538/1682-0363-2018-2-114-120
For citation:
Varlamov E.E., Pampura A.N., Asmanov A.N. Significance of the epidermal barrier and sensitisation to household allergens to the development of atopic march for primary prevention. Bulletin of Siberian Medicine. 2018;17(2):114-120. (In Russ.) https://doi.org/10.20538/1682-0363-2018-2-114-120